Transgender women on oral HIV pre‐exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men

INTRODUCTION: Oral HIV Pre‐Exposure Prophylaxis (PrEP) with tenofovir (TFV) disoproxil fumarate (TDF)/emtricitabine (FTC) is highly effective. Transgender women (TGW) have increased HIV risk, but have been underrepresented in trials. For TGW on oestrogens for gender‐affirming hormone treatment (GAHT...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Int AIDS Soc
Auteurs principaux: Shieh, Eugenie, Marzinke, Mark A, Fuchs, Edward J, Hamlin, Allyson, Bakshi, Rahul, Aung, Wutyi, Breakey, Jennifer, Poteat, Tonia, Brown, Todd, Bumpus, Namandjé N, Hendrix, Craig W
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2019
Sujets:
Research Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6832671/
https://ncbi.nlm.nih.gov/pubmed/31692269
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jia2.25405
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires